Patents by Inventor Robert A. Horlick

Robert A. Horlick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120028301
    Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.
    Type: Application
    Filed: October 12, 2011
    Publication date: February 2, 2012
    Applicant: ANAPTYSBIO, INC.
    Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
  • Publication number: 20110287485
    Abstract: This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID).
    Type: Application
    Filed: May 17, 2011
    Publication date: November 24, 2011
    Applicant: ANAPTYSBIO, INC.
    Inventors: PETER M. BOWERS, ANDREW B. CUBITT, ROBERT A. HORLICK
  • Publication number: 20110183855
    Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.
    Type: Application
    Filed: December 17, 2010
    Publication date: July 28, 2011
    Applicant: ANAPTYSBIO, INC.
    Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
  • Publication number: 20090093024
    Abstract: This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens.
    Type: Application
    Filed: February 20, 2008
    Publication date: April 9, 2009
    Applicant: AnaptysBio, Inc.
    Inventors: Peter M. Bowers, Andrew B. Cubitt, Robert A. Horlick
  • Publication number: 20090075378
    Abstract: The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses.
    Type: Application
    Filed: February 20, 2008
    Publication date: March 19, 2009
    Applicant: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, Andrew B. Cubitt, Peter M. Bowers
  • Patent number: 7084154
    Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: August 1, 2006
    Assignee: Pharmacopeia Drug Disclovery, Inc.
    Inventors: Koc-Kan Ho, John J. Baldwin, Adolph C. Bohnstedt, Steven G. Kultgen, Edward McDonald, Tao Guo, John Richard Morphy, Zoran Rankovic, Robert Horlick, Kenneth C. Appell
  • Patent number: 7041463
    Abstract: Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 receptors from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig, as well as the genes for CXCR2 receptors from chimpanzee, gorilla, orangutan, rhesus, vervet and baboon have been cloned and characterized and are described herein.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: May 9, 2006
    Assignee: Pharmacopeia Drug Discovery, Inc.
    Inventors: Robert Horlick, Jiuquao Zhao, Robert Swanson, Maria Webb, Barbara Strohl, John J. Baldwin, Douglas S. Auld, Xiao Ge Chen
  • Publication number: 20040167119
    Abstract: A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed.
    Type: Application
    Filed: February 11, 2003
    Publication date: August 26, 2004
    Applicant: PHARMACOPEIA, INC
    Inventors: Koc-Kan Ho, John J. Baldwin, Adolph C. Bohnstedt, Steven G. Kultgen, Edward McDonald, Tao Guo, John Richard Morphy, Zoran Rankovic, Robert Horlick, Kenneth C. Appell
  • Publication number: 20030082660
    Abstract: Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 receptors from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig, as well as the genes for CXCR2 receptors from chimpanzee, gorilla, orangutan, rhesus, vervet and baboon have been cloned and characterized and are described herein.
    Type: Application
    Filed: September 9, 2002
    Publication date: May 1, 2003
    Inventors: Robert Horlick, Jiuquao Zhao, Robert Swanson, Maria Webb, Barbara Strohl, John J. Baldwin, Douglas S. Auld, Xiao Ge Chen
  • Patent number: 6469150
    Abstract: The genes for bradykinin B1 receptor from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig have been cloned and characterized. In addition to the delineation of the nucleotide and amino acid sequences, methods for identifying modulators of bradykinin B1 receptor activity using these molecules is also described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: October 22, 2002
    Assignee: Pharmacopeia, Inc.
    Inventors: Robert Horlick, Jiuqiao Zhao, Robert Swanson, Maria Webb, Barbara Strohl
  • Patent number: 6417002
    Abstract: A method for obtaining a eukaryotic cell transfected with an episome involves transfecting the cell with the episome under conditions wherein cells survive that are successfully transfected with the episome. The resulting cells express both a first protein whose expression causes cell death and a second protein whose expression prevents cell death resulting from expression of the first protein.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: July 9, 2002
    Assignee: Pharmacopeia, Inc.
    Inventors: Robert A. Horlick, Daniel Chelsky
  • Patent number: 5976807
    Abstract: A method is described for producing recombinant eukaryotic cell lines expressing multiple proteins of interest. Eukaryotic host cells are transfected with (a) a first episome which contains an EBV origin of replication and a first gene encoding a protein of interest; and (b) a second episome containing an EBV origin of replication and a second gene encoding a protein of interest. Transfected cells are obtained expressing an EBNA 1 protein. The cells are grown under conditions wherein the episomes express the first and second genes.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: November 2, 1999
    Assignee: Pharmacopeia, Inc.
    Inventors: Robert A. Horlick, Bassam B. Damaj, Alan K. Robbins